Claim 1 (Currently Amended). A compound of the following formula:



VII

~~wherein R_2 and R_4 are H;~~



R_{15} is N-substituted amino, ~~or~~ of the following formula: [[;]] or

~~R_{16} is H, alkyl, acyl, alkoxy, aryl, amino, halogen,~~ HET; wherein HET is chosen from pyrrolidine, morpholine, piperazine, piperidine; ~~with the proviso that R_{15} is not NH_2 when R_{16} is H;~~

and pharmaceutically acceptable salts thereof.

Claim 2-9 (Canceled).

Claim 10 (Original). A compound of claim 1 9, wherein HET is pyrrolidine, morpholine.

Claim 11 (Previously Presented). A compound of claim 1 having the following structure:





Claim 12-15 (Canceled).

Claim 16 (Currently Amended). A method of inhibiting or treating ~~amebic infections, including~~ giardiasis, comprising:

administering a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier to a patient in need thereof.

Claim 17 (Currently Amended). A compound of claim 1, of the following formula:





and pharmaceutically acceptable salts thereof.

Claim 18 (Currently Amended). A compound of claim 1, of the following formula:





and pharmaceutically acceptable salts thereof.

Claim 19 (Currently Amended). A compound of claim 1, of the following formula:



and pharmaceutically acceptable salts thereof.